These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes].
    Author: Rajecová E, Kréze A, Klimes I, Cvrkalová A, Lacko A, Langrová H, Hanzen E.
    Journal: Cas Lek Cesk; 1991 Nov 29; 130(22-23):661-3. PubMed ID: 1786587.
    Abstract:
    The objective of this work was to test in type II diabetics with hyperlipoproteinaemia the action of a new analogue of nicotinic acid--Acipimox (Olbetam, Farmitalia Carlo Erba). The investigation comprised 24 patients of whom 16 took for three months Olbetam (250 mg 3 x per day by the oral route) and 8 patients were given placebo. The investigated biochemical parameters were examined before administration of the preparation was started and 4 and 12 weeks following its administration. Contrary to the group taking placebo, in the group taking Olbetam a significant decline of the triglyceride serum level occurred and a slight decline of total serum cholesterol levels and increase of HDL-cholesterol and the atherogenic risk indexes were thus more favourable. The results indicate that Olbetam is a satisfactory hypolipidemic agent for the treatment of diabetic hyperlipoproteinaemia.
    [Abstract] [Full Text] [Related] [New Search]